244 related articles for article (PubMed ID: 10438845)
1. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
Chung RY; Saeki Y; Chiocca EA
J Virol; 1999 Sep; 73(9):7556-64. PubMed ID: 10438845
[TBL] [Abstract][Full Text] [Related]
2. A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.
Lee LY; Schaffer PA
J Virol; 1998 May; 72(5):4250-64. PubMed ID: 9557715
[TBL] [Abstract][Full Text] [Related]
3. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
Nakamura H; Kasuya H; Mullen JT; Yoon SS; Pawlik TM; Chandrasekhar S; Donahue JM; Chiocca EA; Chung RY; Tanabe KK
J Clin Invest; 2002 Apr; 109(7):871-82. PubMed ID: 11927614
[TBL] [Abstract][Full Text] [Related]
4. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
5. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
Kanai R; Tomita H; Shinoda A; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
Gene Ther; 2006 Jan; 13(2):106-16. PubMed ID: 16163378
[TBL] [Abstract][Full Text] [Related]
6. Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.
Manivanh R; Mehrbach J; Knipe DM; Leib DA
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904192
[TBL] [Abstract][Full Text] [Related]
7. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
Kanai R; Zaupa C; Sgubin D; Antoszczyk SJ; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2012 Apr; 86(8):4420-31. PubMed ID: 22345479
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional viral protein γ34.5 manipulates nucleolar protein NOP53 for optimal viral replication of HSV-1.
Meng W; Han SC; Li CC; Dong HJ; Wang XJ
Cell Death Dis; 2018 Jan; 9(2):103. PubMed ID: 29367603
[TBL] [Abstract][Full Text] [Related]
9. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals.
Mohr I; Sternberg D; Ward S; Leib D; Mulvey M; Gluzman Y
J Virol; 2001 Jun; 75(11):5189-96. PubMed ID: 11333900
[TBL] [Abstract][Full Text] [Related]
10. Herpes Simplex Virus 1 Mutant with Point Mutations in
Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
[TBL] [Abstract][Full Text] [Related]
11. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.
Gayral M; Lulka H; Hanoun N; Biollay C; Sèlves J; Vignolle-Vidoni A; Berthommé H; Trempat P; Epstein AL; Buscail L; Béjot JL; Cordelier P
Hum Gene Ther; 2015 Feb; 26(2):104-13. PubMed ID: 25423447
[TBL] [Abstract][Full Text] [Related]
12. The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells.
He B; Chou J; Liebermann DA; Hoffman B; Roizman B
J Virol; 1996 Jan; 70(1):84-90. PubMed ID: 8523596
[TBL] [Abstract][Full Text] [Related]
13. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
14. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma.
Takaoka H; Takahashi G; Ogawa F; Imai T; Iwai S; Yura Y
Virol J; 2011 Jun; 8():294. PubMed ID: 21663640
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Todo T; Martuza RL; Rabkin SD; Johnson PA
Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
[TBL] [Abstract][Full Text] [Related]
16. A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5' end of the latency-associated transcript produces a protein in infected rabbits.
Perng GC; Maguen B; Jin L; Mott KR; Kurylo J; BenMohamed L; Yukht A; Osorio N; Nesburn AB; Henderson G; Inman M; Jones C; Wechsler SL
J Virol; 2002 Aug; 76(16):8003-10. PubMed ID: 12134005
[TBL] [Abstract][Full Text] [Related]
17. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
Kanai R; Tomita H; Hirose Y; Ohba S; Goldman S; Okano H; Kawase T; Yazaki T
Hum Gene Ther; 2007 Jan; 18(1):63-73. PubMed ID: 17238803
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
19. Up to four distinct polypeptides are produced from the γ34.5 open reading frame of herpes simplex virus 2.
Korom M; Davis KL; Morrison LA
J Virol; 2014 Oct; 88(19):11284-96. PubMed ID: 25031346
[TBL] [Abstract][Full Text] [Related]
20. Characterization of ICP6::lacZ insertion mutants of the UL15 gene of herpes simplex virus type 1 reveals the translation of two proteins.
Yu D; Sheaffer AK; Tenney DJ; Weller SK
J Virol; 1997 Apr; 71(4):2656-65. PubMed ID: 9060618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
